Stochastic modelling of the eradication of the HIV-1 infection by stimulation of latently infected cells in patients under highly active anti-retroviral therapy

被引:12
|
作者
Sanchez-Taltavull, Daniel [1 ,4 ]
Vieiro, Arturo [2 ]
Alarcon, Tomas [3 ,4 ,5 ,6 ]
机构
[1] Ottawa Hosp, Res Inst, Regenerat Med Program, Ottawa, ON K1H 8L6, Canada
[2] Univ Barcelona, Dept Matemat Aplicada & Anal, E-08007 Barcelona, Spain
[3] ICREA, Barcelona, Spain
[4] Ctr Recerca Matemat, Edifici C,Campus Bellaterra, Barcelona 08193, Spain
[5] Univ Autonoma Barcelona, Dept Matemat, E-08193 Barcelona, Spain
[6] Barcelona Grad Sch Math BGSMath, Barcelona, Spain
关键词
HIV-1; HAART; Latently infection; Stochastic modelling; Antigen stimulation; IN-VIVO; VIRAL DYNAMICS; T-CELLS; RESERVOIR; PERSISTENCE; DECAY; DRUG; LYMPHOCYTES; EVOLUTION; LOAD;
D O I
10.1007/s00285-016-0977-5
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
HIV-1 infected patients are effectively treated with highly active anti-retroviral therapy (HAART). Whilst HAART is successful in keeping the disease at bay with average levels of viral load well below the detection threshold of standard clinical assays, it fails to completely eradicate the infection, which persists due to the emergence of a latent reservoir with a half-life time of years and is immune to HAART. This implies that life-long administration of HAART is, at the moment, necessary for HIV-1-infected patients, which is prone to drug resistance and cumulative side effects as well as imposing a considerable financial burden on developing countries, those more afflicted by HIV, and public health systems. The development of therapies which specifically aim at the removal of this latent reservoir has become a focus of much research. A proposal for such therapy consists of elevating the rate of activation of the latently infected cells: by transferring cells from the latently infected reservoir to the active infected compartment, more cells are exposed to the anti-retroviral drugs thus increasing their effectiveness. In this paper, we present a stochastic model of the dynamics of the HIV-1 infection and study the effect of the rate of latently infected cell activation on the average extinction time of the infection. By analysing the model by means of an asymptotic approximation using the semi-classical quasi steady state approximation (QSS), we ascertain that this therapy reduces the average life-time of the infection by many orders of magnitudes. We test the accuracy of our asymptotic results by means of direct simulation of the stochastic process using a hybrid multi-scale Monte Carlo scheme.
引用
收藏
页码:919 / 946
页数:28
相关论文
共 50 条
  • [1] Stochastic modelling of the eradication of the HIV-1 infection by stimulation of latently infected cells in patients under highly active anti-retroviral therapy
    Daniel Sánchez-Taltavull
    Arturo Vieiro
    Tomás Alarcón
    Journal of Mathematical Biology, 2016, 73 : 919 - 946
  • [2] Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy
    Mark E. Sharkey
    Ian Teo
    Thomas Greenough
    Natalia Sharova
    Katherine Luzuriaga
    John L. Sullivan
    R. Pat Bucy
    Leondios G. Kostrikis
    Ashley Haase
    Claire Veryard
    Raul E. Davaro
    Sarah H. Cheeseman
    Jennifer S. Daly
    Carol Bova
    Richard T. Ellison
    Brian Mady
    Kwan Kew Lai
    Graeme Moyle
    Mark Nelson
    Brian Gazzard
    Sunil Shaunak
    Mario Stevenson
    Nature Medicine, 2000, 6 : 76 - 81
  • [3] Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy
    Sharkey, ME
    Teo, I
    Greenough, T
    Sharova, N
    Luzuriaga, K
    Sullivan, JL
    Bucy, RP
    Kostrikis, LG
    Haase, A
    Veryard, C
    Davaro, RE
    Cheeseman, SH
    Daly, JS
    Bova, C
    Ellison, RT
    Mady, B
    Lai, KK
    Moyle, G
    Nelson, M
    Gazzard, B
    Shaunak, S
    Stevenson, M
    NATURE MEDICINE, 2000, 6 (01) : 76 - 81
  • [4] Worsening and unmasking of tuberculosis in HIV-1 infected patients after initiating highly active anti-retroviral therapy in Uganda
    Baalwa, Joshua
    Mayanja-Kizza, Harriet
    Kamya, Moses R.
    John, Laurence
    Kambugu, Andrew
    Colebunders, Robert
    AFRICAN HEALTH SCIENCES, 2008, 8 (03) : 190 - 195
  • [5] Changes in immune parameters in HIV-1 infected children during highly active anti-retroviral therapy (HAART).
    Westby, M
    Watkins, AM
    Drake, J
    Wills, B
    Cammack, N
    Sharland, M
    AIDS, 1998, 12 : S95 - S95
  • [6] The development of tuberculosis in patients receiving highly active anti-retroviral therapy for HIV infection
    Breen, RAM
    Smith, CJ
    Cropley, I
    Johnson, MA
    Lipman, MCI
    THORAX, 2004, 59 (01) : 37 - 37
  • [7] UROLITHIASIS AMONG HIV INFECTED PATIENTS IN THE HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY (HAART) ERA
    Mirheydar, Hossein
    Raheem, Omer
    Palazzi-Churas, Kerrin
    Chenoweth, Marianne
    Lakin, Charles M.
    Sur, Roger L.
    JOURNAL OF UROLOGY, 2012, 187 (04): : E907 - E908
  • [8] Dysregulated immunophenotypic attributes of plasmacytoid but not myeloid dendritic cells in HIV-1 infected individuals in the absence of highly active anti-retroviral therapy
    Benlahrech, A.
    Yasmin, A.
    Westrop, S. J.
    Coleman, A.
    Herasimtschuk, A.
    Page, E.
    Kelleher, P.
    Gotch, F.
    Imami, N.
    Patterson, S.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2012, 170 (02): : 212 - 221
  • [9] Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy
    Tae-Wook Chun
    Delphine Engel
    Stephanie B. Mizell
    Claire W. Hallahan
    Maria Fischette
    Sohee Park
    Richard T. Davey
    Mark Dybul
    Joseph A. Kovacs
    Julia A. Metcalf
    JoAnn M. Mican
    M. Michelle Berrey
    Lawrence Corey
    H. Clifford Lane
    Anthony S. Fauci
    Nature Medicine, 1999, 5 : 651 - 655
  • [10] Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy
    Chun, TW
    Engel, D
    Mizell, SB
    Hallahan, CW
    Fischette, M
    Park, S
    Davey, RT
    Dybul, M
    Kovacs, JA
    Metcalf, JA
    Mican, JM
    Berrey, MM
    Corey, L
    Lane, HC
    Fauci, AS
    NATURE MEDICINE, 1999, 5 (06) : 651 - 655